The Latest Analyst Ratings For Editas Medicine

By Benzinga Insights

Throughout the last three months, 4 analysts have evaluated Editas Medicine (NASDAQ: EDIT ), offering a diverse set of opinions from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over th

You are viewing a robot-friendly page.Click hereto reload in standard format.